Use this url to cite publication: https://hdl.handle.net/20.500.12512/99002
Options
Ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles : [skaitytas pranešimas] / A Ciginskiene, A Dambrauskiene, D Adukauskiene, V Pilvinis, I Zubaviciute
Type of publication
Konferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
Author(s)
Title
Ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles : [skaitytas pranešimas] / A Ciginskiene, A Dambrauskiene, D Adukauskiene, V Pilvinis, I Zubaviciute
Date Issued
Date Issued |
---|
2019-03-19 |
Extent
p. 1-1.
Is part of
ISICEM 2019 - 39th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium, 19-22 March 2019 / Department of Intensive Care and Emergency Medicine of Erasme University Hospital [et al.]. .
Version
Originalus / Original
Description
no. A116
Category 1: Infections + Antimicrobials. Category 2: Respiratory: other.
Field of Science
Abstract
Introduction: Acinetobacter baumannii (AcB) remains one of the most prevalent ventilator-associate pneumonia (VAP) causing pathogen. In recent years, share of drug resistant AcB strains across Europe was found to be steadily increasing. Consequently, in 2017, AcB was included in the WHO global priority list of drug-resistant bacteria to highlight the need for the research development. The aim of this study was to identify the relation of risk factors for ventilator-associated pneumonia (VAP) and mortality with drug resistance profiles of AcB. Methods: A retrospective cohort study of patients treated in medical-surgical ICUs with drug-resistant strains of AcB as pathogens of VAP over a 2-year period was carried out. Results: The data of 60 medical-surgical ICUs patients with VAP due to drug-resistant AcB were analysed. The proportions of multidrug-resistant (MDR), extensively drug-resistant (XDR), and potentially pandrug-resistant (pPDR) AcB were 13.3%, 68.3%, and 18.3%, respectively (p<0.05). The SAPS II scores on ICU admission were 42.6, 48.7, and 49 (p<0.048); hospital length of stay prior to ICU was 0, 1, and 2 days (p<0.036), prior to mechanical ventilation - 0, 0, and 3 days (p<0.013), and carbapenem use prior to VAP - 50%, 29.3%, and 18.2% (p <0.036) in MDR, XDR, pPDR AcB VAP groups respectively. The overall in-hospital mortality rate was 63.3%. In MDR, XDR, and pPDR AcB VAP groups it was 62.5%, 61.3%, and 72.7%, respectively (p = 0.772). Conclusion: The VAP risk factors: higher SAPS II score, increased hospital length of stay prior to ICU and mechanical ventilation were related to higher resistance profile of AcB. Carbapenem use was found to be associated with the risk of MDR AcB VAP. Mortality due to drug-resistant AcB VAP was high, but not associated with AcB drug resistance profile. Thus, timely mechanical ventilation and ICU treatment may reduce the risk of VAP due to higher drug-resistant AcB, especially
Type of document
type::text::conference output::conference proceedings::conference paper
Other Identifier(s)
(LSMU ALMA)990000988870107106
Coverage Spatial
Belgija / Belgium (BE)
Language
Anglų / English (en)